CASI Pharmaceuticals (CASIF) Tax Provisions (2023)
CASI Pharmaceuticals' (CASIF) quarterly Tax Provisions came in at $80000.0 in Q2 2023.
Powered by 
Analysis
CASI Pharmaceuticals (CASIF) Tax Provisions (2023) Analysis & Trends
CASI Pharmaceuticals (CASIF) has reported Tax Provisions for 1 consecutive years, with $80000.0 the latest figure, recorded in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -1.01 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -407.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -524.23 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 165.91 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 39.70 Mn |
| 10 | CASI Pharmaceuticals | 2.39 Mn | -1.38 Mn | - | - |